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Abstract
Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we 
examined the DNA mutations and chromosome arm-level aneuploidy within tumours with low, intermediate and high cell-cycle 
activity in 9515 pan-cancer patients with 32 different tumour types. Boxplots showed that cell-cycle activity varied broadly 
across and within all cancers. TP53 and PIK3CA mutations were common in all cell cycle score (CCS) tertiles but with 
increasing frequency as cell-cycle activity levels increased (P < 0.001). Mutations in BRAF and gains in 16p were less frequent in 
CCS High tumours (P < 0.001).  In  Kaplan–Meier analysis, patients whose tumours were CCS Low had a longer Progression 
Free Interval (PFI) relative to Intermediate or High (P < 0.001) and this significance remained in multivariable analysis (CCS 
Intermediate: HR = 1.37; 95% CI 1.17–1.60, CCS High: 1.54; 1.29–1.84, CCS Low = Ref). These results demonstrate that 
whilst similar DNA alterations can be found at all cell-cycle activity levels, some notable exceptions exist. Moreover, 
independent prognostic information can be derived on a pan-cancer level from a simple measure of cell-cycle activity.
Introduction
The Nobel prize winning research of Hartwell [1], Nurse
[2, 3] and Hunt [4] in the nineteen seventies and eighties
fundamentally changed our understanding of the cell cycle
and provided broad insight into the molecules governing its
regulation. These seminal discoveries have shaped our
modern view of the cell cycle and its separation into four
distinct phases commonly referred to as G1, S, G2 and M.
Transitions between these phases are governed by the cyclin
family of proteins along with their binding partners
the cyclin dependent kinases (CDKs) [5]. Disruptions to the
function of cyclin-CDK holoenzymes or other cell cycle
pathway members can lead to impaired control over the
cycle and sustained proliferation—a hallmark of cancer [6].
Large scale pan-cancer studies have sought to understand
human malignancies at a molecular level through the inte-
gration of multiple high-throughput data types. This
approach has yielded a number of clinically relevant find-
ings including the coalescence of lung squamous, head and
neck, and some bladder cancers into a single pan-cancer
subtype and the ability to classify tumours into prognostic
subgroups at a pan-cancer level [7]. More recently, data
from over 11,000 patients has shown actionable mutations
in up to 57% of tumours [8], a positive correlation between
aneuploidy and cell-cycle genes [9], and frequent co-
alterations in the p53 and cell-cycle pathways [10]. To date,
the analysis of genomic aberrations in these studies have
typically focused on all pan-cancer tumours at once [8],
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within subgroups of tumours that have clustered together on
the basis of DNA, RNA and protein expression—termed the
iClusters [8], or within tumours with a common genetic
alteration such as chromosome 3p loss [9]. Given the
varying degrees of oncogenic pathway activation/suppres-
sion across cancer types [10], we hypothesised that basing
genomic analyses on the magnitude of pathway activity
may also provide important biological information and
clinical insight. In view of the fundamental biological role
of the cell cycle in cancer and the frequent genomic
alterations of its pathway members, it represents a com-
pelling choice for a pathway activity-based analysis.
Here, in order to test our hypothesis, we compare the most
prevalent genomic alterations in tumours with low, inter-
mediate and high levels of cell-cycle activity by integrating
data from multiple genomic platforms in over 9000 tumours
from The Cancer Genome Atlas (TCGA). Specifically, we
examine gene expression levels, gene mutational frequency
and chromosome arm-level alterations across pan-cancer
tumours grouped into low, intermediate and high tertiles of
cell-cycle activity on the basis of our cell cycle score (CCS)
gene signature [11, 12]. Finally, we also determine the clinical
relevance of this signature across and within cancer types
using survival analyses including Kaplan–Meier graphs and
multivariable Cox proportional hazards modelling adjusting
for patient and tumour characteristics.
Results
Cohort clinico-pathological characteristics in
relation to CCS subgroups
In line with our aim to compare genomic alterations in
tumours with differing levels of cell-cycle activity we
applied our CCS signature (genes are shown in Supple-
mentary Table 1) to gene expression data from the tumours
of 9515 pan-cancer patients. Clinico-pathological char-
acteristics for the pan-cancer cohort split by low, inter-
mediate and high CCS tertile classifications are shown in
Table 1 and a CONSORT diagram showing the exclusion
criteria for this study is shown in Supplementary Fig. 1.
Statistically significant associations were found between
patient age, gender, pathological stage, radiotherapy and
CCS subgroups (Table 1, Chi-squared test: P < 0.001 for all
comparisons). After adjusting for cancer type, only stage
and radiotherapy remained statistically significant whereby
CCS High tumours were more likely to be stage IV and to
have received radiotherapy (data not shown).
Broad variation in cell-cycle activity across cancers
and COCA subtypes
We next assessed tumour cell-cycle activity by creating
pan-cancer, Cluster of cluster assignment (COCA) and
iCluster boxplots using the continuous CCS. We found the
highest levels of cell-cycle activity in Lymphoid Neoplasm
Diffuse Large B-cell Lymphoma (DLBC), Testicular Germ
Cell tumours (TGCT), Head and Neck squamous cell car-
cinoma (HNSC) and Cervical squamous cell carcinoma and
endocervical adenocarcinoma (CESC) tumours and the
lowest in Kidney Chromophobe (KICH), Pheochromocy-
toma and Paraganglioma (PCPG), Kidney renal papillary
cell carcinoma (KIRP) and Prostate adenocarcinoma
(PRAD) tumours (Fig. 1a). Similar results were found using
the COCA algorithm—a classification strategy that clusters
samples by integrating information from multiple individual
cross platform technologies, with CA17 (TCGT) and CA4
(PAN-SCC, mainly HNSC, LUSC and CESC tumours)
forming the top two subgroups with the highest cell-cycle
activity (Fig. 1b). CA10 (Breast Invasive Carcinoma
(BRCA), basal-like) and CA25 (Haematologic/lymphatic,
mainly Thymoma (THYM) and DLBC tumours), also
showed high cell-cycle activity, whilst CA1 (CNS/Endo-
crine, mainly PCPG tumours), CA14 (PRAD) and C21
(PAN-Kidney) showed the lowest levels of all COCA
subtypes (Fig. 1b). Analogous results were noted using the
Table 1 Clinical characteristics of all patients split by CCS—pan-
cancer.
Variables Pan-cancer (n = 9515)
Low n (%) Intermediate n (%) High n (%)
3145 (33) 3184 (33.5) 3186 (33.5) p
Age
≤54 1290 (41) 876 (28) 1061 (34) <0.001
54–66 1044 (33) 1062 (33) 996 (31)
≥66 808 (26) 1236 (39) 1119 (35)
Missing cases= 23
Gender
Male 1771 (56) 1372 (43) 1494 (47) <0.001
Female 1374 (44) 1812 (57) 1692 (53)
Pathological stage
Stage I 859 (45) 601 (26) 444 (20) <0.001
Stage II 480 (25) 820 (35) 768 (35)
Stage III 419 (22) 639 (28) 575 (27)





No 1954 (73) 2047 (73) 1820 (65) <0.001
Yes 709 (27) 770 (27) 993 (35)
Missing cases= 1222
aI/II NOS-Stage 0/IS/X, in bold significant p < 0.05.
iCluster classification strategy (Supplementary Fig. 2).
Examining cell-cycle activity clusters using heatmap ana-
lysis demonstrated that tumours with low levels of cell-
cycle activity (and thus classified as CCS Low) show low
expression of the majority of genes in all cell cycle phases
(G1–M), whilst the opposite is true for tumours with high
levels of cell-cycle activity (Fig. 1c, compare tumours with
black column-side colour to those with yellow).
TP53 and PIK3CA mutations display increasing
frequency across cell-cycle activity subgroups
To more clearly delineate the frequency of DNA mutations
in relation to the magnitude of cell-cycle activity we next
examined the mutational frequency of 299 well defined
oncogene and tumour suppressor driver genes within CCS
subgroups. TP53 was found to be the most mutated gene in
all three CCS subgroups and displayed an increase in
mutational frequency with increasing CCS activity (Fig. 2a,
Supplementary Table 2, Chi-squared test: P < 0.001). In
CCS Low tumours 40% of TP53 mutations were found in
LGG, whereas in CCS High tumours TP53 mutations were
most common in HNSC (18%), LUSC (17%) and BRCA
(13%) (Highlighted in Fig. 2a). PIK3CA was the second-
most commonly mutated gene in CCS Intermediate and
High tumours and fifth-most common in CCS Low tumours
(Fig. 2a). It is also more frequently mutated in CCS Inter-
mediate and High tumours relative to CCS Low (Supple-
mentary Table 2, P < 0.001). PIK3CA mutations in BRCA
and Uterine Corpus Endometrial Carcinoma (UCEC) were
common across all CCS subgroups and were additionally
found in HNSC and CESC in CCS High tumours (Fig. 2a).
Of interest, whilst BRAF mutations were prominent in Low
and Intermediate subgroups as the third and eleventh most
mutated gene respectively, it was absent from the top 15 in
CCS High tumours (Fig. 2a, red arrows, Supplementary
Table 2, P < 0.001). These findings suggest genes other than
BRAF are more commonly mutated in tumours with high
Fig. 1 CCS score across cancer types and COCA subtypes. Box-
plots comparing CCS across (a) pan-cancer types and (b) COCA
subtypes. Numbers in parentheses represent number of tumours in
each cancer type and/or COCA subtype. c Heatmap of CCS genes
across pan-cancer tumours. Heatmap colside colours (horizontal,
above heatmap) represent cell cycle score, cancer types and COCA
subtypes as indicated in figure legend. Rowside colours (vertical, left
hand side of heatmap) represent cell cycle phases.
cell-cycle activity. Of note, the increased number of BRAF
mutations in CCS Low tumours is mainly driven by a single
tumour type—Thyroid carcinoma (THCA) (THCA, pink
colour under red arrow in Fig. 2a), whereas in CCS
Intermediate (and High) tumours BRAF mutations are
mostly found in Skin Cutaneous Melanoma (SKCM)
Fig. 2 Top 15 most commonly mutated genes or chromosomal
arm-level alterations within CCS subgroups. Pan-cancer tumours
were divided into tertiles on the basis of low, intermediate or high
CCS. Within each subgroup the Top 15 (a) most frequently mutated
oncogenes and tumour suppressor genes, (b) arm-level gains and (c)
arm-level losses are shown. Cancer type colour key is shown at the
bottom of the figure. Red arrows indicate BRAF mutations and 16p
gains in CCS Low and Intermediate subgroups.
(Supplementary Table 3). The top 50 most frequently
mutated genes in all CCS subgroups are shown in Supple-
mentary Table 4.
Higher levels of chromosomal gains and losses in
CCS Intermediate and High tumours
We next performed the same subgroup analysis, but this
time focusing on chromosome arm-level gains and losses.
All CCS subgroups showed a high number of gains to arms
20q, 8q and 7p and losses to arms 17p and 8p (Fig. 2b, c,
respectively, all CCS subgroups). Moreover, these chro-
mosomal aberrations all displayed an increase in frequency
with increasing CCS activity (Supplementary Table 2, Chi-
squared test: P < 0.001 for all comparisons, not adjusted for
multiple testing). Overall, gains in KIRP (Fig. 2b, high-
lighted) and losses in PCPG cancers (Fig. 2c, highlighted)
were more common in CCS Low tumours relative to CCS
Intermediate and High subgroups, as could be anticipated
given the low cell-cycle activity levels displayed by these
tumour types and their grouping into the CCS Low tumour
subgroup (Fig. 1a). Analogous to our BRAF mutation find-
ings, gains to 16p (Fig. 2b, red arrows) were more common
in CCS Low and Intermediate subgroups relative to the CCS
High subgroup (Supplementary Table 2, P < 0.001). 29% of
16p gains are found in KIRP in CCS Low tumours, whereas
they occur most commonly in BRCA in CCS Intermediate
and High tumours (Supplementary Table 3). The frequency
of chromosomal arm gains and losses in all CCS subgroups
are shown in Supplementary Table 5.
Next, we examined genomic alterations more broadly
within CCS subgroups and found the frequency of gene
mutations and chromosomal arm gains and losses to be
greater in CCS Intermediate and High groups relative to
Low (Fig. 3a–c, Tukey HSD test, 3A top 50 DNA muta-
tions: P < 0.001 and P < 0.001, 3B chromosomal gains: P=
0.018 and P < 0.001 and losses 3C: P < 0.001 and P < 0.001
for Low vs. Intermediate and High, respectively). Similarly,
using the recently derived aneuploidy score [9]—a measure
of the total number of chromosome arms with arm-level
Fig. 3 Boxplots comparing frequency of DNA alterations across
CCS subgroups. Pan-cancer tumours were divided into tertiles on the
basis of low, intermediate or high CCS. Within each subgroup the
number of (a) total mutations in the top 50 most mutated oncogenes or
tumour suppressor genes, (b) total chromosomal arm-level gains, (c)
total chromosomal arm-level losses and (d) aneuploidy score are
shown. e Kaplan–Meier analysis of CCS subgroups with Progression
free Interval (PFI) as clinical endpoint. Low/Inter/High= Low/Inter-
mediate/High CCS subgroups, p values in boxplots (based on
ANOVA with post-hoc Tukey HSD test)=NS > 0.05, * < 0.05,
** < 0.01, *** < 0.001; p value in the Kaplan–Meier curves refer to
long-rank tests.
copy number changes in a given sample, we also found a
statistically significant increase with increasing CCS activ-
ity levels (Fig. 3d, P < 0.001 for all comparisons).
CCS signature provides independent prognostic
information at pan-cancer level
We next assessed the relationship between CCS and Pro-
gression Free Interval (PFI) using Kaplan–Meier and mul-
tivariable Cox proportional hazard regression model
analyses. In univariate Kaplan–Meier analysis patients
whose tumours were classified as CCS Low had a sig-
nificantly longer PFI relative to those classified as CCS
Intermediate or High (Fig. 3e, log-rank test: P < 0.001).
This significance remained when adjusting for tumour type,
age, gender, pathological stage and radiotherapy in Cox
proportional hazard analysis (Table 2, CCS Intermediate:
HR 1.37 95% CI 1.17–1.60, CCS High: HR 1.54 95% CI
1.29–1.84, tumour type not shown). The upper age tertile
(≥66) remained statistically significant in the same model
(HR 1.19 95% CI 1.05–1.35 vs. Ref), as did all pathological
stages vs. the Stage I model reference group. As many
cancers contain additional molecular subgroups (e.g. breast
cancer) we also performed a similar analysis but adjusting
for COCA subtypes rather than pan-cancer types and found
comparable independent prognostic capacity for the CCS
(data not shown).
In order to more closely examine individual cancer types
where the signature splits tumours into two or three CCS
subgroups, we again performed Kaplan–Meier and Cox
proportional hazard modelling but this time focusing on
individual cancers. CCS provided significant independent
prognostic information in four cancer types: Kidney renal
clear cell carcinoma (KIRC) (P= 0.042), LGG (P < 0.001),
Sarcoma (SARC) (P= 0.001) and Uveal Melanoma (UVM)
(P= 0.013, Supplementary Fig. 3, alphabetical ordering,
adjusted for multiple testing). Finally, as the CCS sub-
groups are based on a tertile split of cell-cycle activity on a
pan-cancer level, we hypothesised that deriving subgroups
in this manner may provide superior prognostic information
to a simple tertile split within (intra) each cancer type. To
test this hypothesis, we compared our pan-cancer CCS
tertile subgroups to intra-cancer CCS tertile subgroups. We
found that whilst both cut-offs provide significant
prognostic information in the above four cancer types
(Compare Kaplan–Meier curves for pan-cancer CCS to
intra-cancer CCS, Supplementary Fig. 4), a pan-cancer cut-
off provides more prognostic information calculated by the
likelihood ratio (LR) test, in KIRC (LR= 24.7), LGG
(LR= 31.1), SARC (LR= 18.5) and UVM cancers (LR=
17.1), Table 3, compare pan-cancer column to intra-cancer).
These findings suggest that deriving transcriptional bio-
marker cut-points on a pan-cancer level may be
advantageous relative to deriving them in a single cancer
type. For the sake of completeness, hazard ratios and 95%
confidence intervals for pan-cancer and intra-cancer tertile
subgroups in individual cancers are shown in Supplemen-
tary Table 6.
Discussion
The present study integrates gene expression, DNA mutation,
DNA copy number and clinico-pathological data from 9515
pan-cancer patients in order to better understand the DNA
level alterations present in tumours with low, intermediate and
high cell-cycle activity. Our main findings show first, that
cell-cycle activity varies broadly across and within cancer
types; second, that TP53, PIK3CA and chromosomal altera-
tions (including gains to 20q, 8q, 7p and losses to arms 17p
and 8p) occur with increasing frequency in tumours with
increasing cell-cycle activity; third, whilst in general similar
mutations/arm-level alterations are present within tumours
Table 2 Multivariate evaluation of prognostic markers in patients
characterised by Cell Cycle Score.
Variables Pan-cancer (n= 5421)a
N (%) HR 95% CI p
Age
≤54 1679 (31) Ref − −
54–66 1761 (32) 1.04 0.91–1.18 0.551
≥66 1981 (37) 1.19 1.05–1.35 0.008
Missing cases= 23
Gender
Male 2757 (51) Ref − −
Female 2664 (49) 0.96 0.87–1.07 0.483
Pathological stage
Stage I 1561 (29) Ref − −
Stage II 1852 (34) 1.60 1.38–1.86 <0.001
Stage III 1378 (25) 2.41 2.08–2.79 <0.001
Stage IV 630 (12) 5.04 4.21–6.03 <0.001
Missing cases= 3118
Radiotherapy
No 3997 (74) Ref − −
Yes 1424 (26) 0.97 0.84–1.11 0.658
Missing cases= 1222
Cell cycle score
Low 1505 (28) Ref − −
Intermediate 2013 (37) 1.37 1.17–1.60 <0.001
High 1903 (35) 1.54 1.29–1.84 <0.001
In bold significant p < 0.05.
Ref reference groups, N number of patients, HR hazard ratio, CI
confidence interval.
aAdjusted for cancer types.
with low, intermediate and high cell-cycle activity, mutations
in BRAF and gains in 16p were less frequent in tumours with
high cell-cycle activity; and fourth, that deriving cut-points for
biomarkers on a pan-cancer level may provide more prog-
nostic information than deriving them within specific cancer
types. These analyses are the first to provide broad insight on
the genetic alterations occurring within tumours grouped on
the basis of cell-cycle activity in order to advance our
understanding of a pathway that is frequently dysregulated in
human malignancies.
In pan-cancer analyses, TP53, PIK3CA, KRAS, PTEN
and ARID1A genes have all been previously demonstrated
to be mutated in over 15 different cancer types [8]. These
genes also featured heavily in our mutational analysis with
TP53 and PIK3CA mutations showing the high- mutational
frequency across CCS subgroups. This implies that muta-
tions in these genes are found in tumours with a broad
range of cell -cycle activity and are not just associated with
highly cycling cancers, despite their very clear links to cell-
cycle progression [13, 14]. Whilst we found the ARID1A
gene to be mutated in all CCS subgroups, BRAF was
notable for only being found in the top 15 of the CCS Low
and Intermediate subgroups, implying that other genes are
more commonly mutated in tumours with high cell-cycle
activity, such as TP53 and PIK3CA. This result is partially
driven by the cancer types found in each of the CCS sub-
groups, e.g. BRAF mutations are predominantly found in
THCA cancers in the CCS Low subgroup and SKCM in
CCS Intermediate and High tumours. It is important to
highlight that CCS tumour subgroups were derived on the
basis of biological cell cycle pathway activity alone. Our
aim was to provide map/characterise the DNA aberrations
within tumours on the basis of pathway magnitude, as such,
even if a specific aberration is enriched owing to a certain
tumour type, it is still one characteristic of tumours with
low levels of cell-cycle activity, albeit one associated with
a specific cancer type.
It has recently been demonstrated that tumour aneuploidy
is inversely correlated to immune signalling genes and posi-
tively correlated to cell cycle and pro-proliferation pathways
[9]. Our findings are in line with these showing a step wise
increase in aneuploidy score with increasing CCS activity
levels. Related to this, whilst most of predominant chromo-
some arm-level alterations we observed overlapped with those
from the pan-cancer publication [9], our within subgroup
analysis yielded some novel findings. In particular, and ana-
logous to our mutational results, we found that specific gains
(16p) were present in the CCS Intermediate and High sub-
groups only (Fig. 2b, c, red arrows). This raises the possibility
that this chromosomal alteration could potentially be used as
novel clinical biomarkers for more indolent tumours in can-
cers of unknown primary origin.
We found that our CCS gene expression signature, which
has been previously applied in a breast cancer setting [11, 12],
provided independent prognostic information on a pan-cancer
level. This signature was originally conceived as a simple
biological measure of cell-cycle activity in response to the
dependence of more established commercial gene expression
signatures on multiple cell cycle/cell proliferation genes for
their prognostic capacity [15]. The signature genes were chosen
through the aggregation of three different biological pathway
databases [16–18], meaning that it is not cancer-specific and
can be applied to any tissue sample. In keeping with its
descriptive nature, we have not attempted to maximise the
signature’s prognostic capacity through selection of genes that
are the strongest predictors of the study’s clinical endpoint—
PFI. Despite this, the signature performed well in both
Kaplan–Meier and multivariable analyses, likely owing to its
ability to select for faster growing, more aggressive tumours.
As we are applying the CCS to a pan-cancer cohort, the
prognostic capacity of the signature should be viewed in the
context of all cancers and in general, not necessarily within
specific cancer types. For example, when we split the con-
tinuous CCS into tertiles of activity the majority of prostate
Table 3 Prognostic value of Cell
Cycle signature (CCS) based on
likelihood ratio (LR-X2) and
concordance index (C-index).
Pan-cancer and intra-cancer
Models Cell cycle score
Total Events Pan-Cancer Intra-cancer
Univariate C-index LR-X2 p C-index LR-X2 p
KIRC 480 148 0.589 24.7 <0.001 0.567 9.9 0.001
LGG 506 192 0.609 31.1 <0.001 0.627 21.9 <0.001
SARC 242 124 0.610 18.5 <0.001 0.614 14.3 <0.001
UVM 79 24 0.732 17.1 <0.001 0.707 11.5 <0.001
Events: Progression Free Interval (PFI) events in which patients had a new tumour whether it was a
progression of disease, local recurrence, distant metastasis, new primary tumours all sites, or died with the
cancer without new tumour event. In bold significant p < 0.05.
KIRC kidney renal clear cell carcinoma, LGG brain lower grade glioma, SARC sarcoma, UVM uveal
melanoma, CCS cell cycle score, LR-X2 likelihood ratio, C-index concordance index.
cancers (PRAD) are classified into the CCS Low subgroup and
thus as “good” prognosis based on our analyses. Conversely,
glioblastoma cancers (GBM) were predominantly classified
into CCS Intermediate and High subgroups and thus as “poor”
prognosis. In line with this, the median time to a PFI event for
PRAD patients in the pan-cancer cohort is 18.4 months,
whereas for GBM it’s 6.1 months [19]. As such, the prognostic
capacity for the CCS signature when applied to all tumours
cannot be determined on the basis of its strength within in a
single cancer type, but only when considered in the context of
all cancers. Interestingly, however, some cancers were split into
two or three different CCS subgroups and upon further
examination of these cancer types we found that deriving CCS
tertiles of activity on a pan-cancer level may provide more
prognostic information than deriving them within a specific
cancer type. This could be of utility in a clinical setting where a
gene transcript is being used as a biomarker for treatment
response, such as the recent example of cyclin E expression
and Palbociclib efficacy in metastatic breast cancer patients
[20]. In this instance it is conceivable that re-defining a cyclin E
cut-point on the basis of pan-cancer expression levels of the
gene may more clearly delineate which patients are likely to be
resistant to the drug.
When applying a gene expression signature to any
dataset a choice regarding the best cutoffs for sample
subgrouping is typically inherent to the analysis. Here, we
chose to divide the continuous CCS into three equal
groups resulting in low, intermediate and high expression
subgroups. This decision was largely based on both our
experience with other gene expression signatures in the
breast cancer field where three subgroups are common,
such as for the 21-gene recurrence score [21] and the
biology-based gene expression modules [22]. Moreover,
given that the CCS is continuum of values (as shown in
Fig. 1) without any clear bimodal distribution, it does not
make sense to force a simple binary high/low grouping on
the data. Instead, we opted for tertiles that reflect this
continuum with high and low expression groups and the
addition of a third intermediate subgroup to cover the
range of samples transitioning from low to high expres-
sion. Another important point to consider is that we are
applying the CCS signature to data extracted from an
entire tumour and as such are getting an average gene
signal across the entire sample. This means that hetero-
geneity in terms of the cellular composition of the tumour
and in terms of expression of the CCS in different tumour
regions is not taken into account. Many newer technolo-
gies including single-cell sequencing and spatial tran-
scriptomics can be used to examine tumour heterogeneity
at single-cell resolution [23], however, as this type of data
is not currently available for the tumours of the pan-
cancer cohort we cannot assess the intratumour variation
of the CCS in this material. A second, more traditional
way to take heterogeneity into account is through the
examination of whole tumour sections under the micro-
scope. Given that the CCS is interlinked with cell pro-
liferation, which in turn is an important component of
tumour grading (in the form of mitotic count), one could
speculate as to the merits of grading in addition in to or in
place of applying the CCS. Unfortunately, tumour grading
information was missing for over 50% of the tumours
included in this study meaning it was not included in
multivariable analyses. More importantly, grading sys-
tems differ greatly between cancer types, for example the
three-level Nottingham histologic grade is used in breast
cancer whilst Gleason grading with up to five different
groups is used in prostate cancer. This renders the appli-
cation of grade at a pan-cancer level currently unfeasible
and relatedly, we have previously demonstrated the pro-
pensity of the CCS and other gene expression signatures
to outperform ocular assessment of the proliferation
marker Ki67 on whole tumour sections [11, 24].
There are three main strengths to our study; first, we
utilise a novel methodology to examine the DNA alterations
in subgroups of tumours that is based on the magnitude of
cell-cycle activity both across and within cancer types; sec-
ond, our analysis provides an expansive, descriptive over-
view of the frequency of DNA mutations and chromosomal
gains and losses in subgroups of low, intermediate and high
cell- cycle activity; and third, we demonstrate the transla-
tional relevance of our work by relating our CCS signature to
a clinical survival endpoint —PFI. The limitations are as
follows; first, our analysis focuses on DNA and RNA tech-
nologies only, with no protein or methylation array data
included; second, we chose to study broad chromosomal
gains and losses rather than gene-centric copy number
changes—this was to avoid a situation where the most
changed genes within a given CCS subgroup would all come
from the same chromosomal location; third, we did not adjust
the CCS for every molecular subgroup within every cancer
type in multivariable analysis—this is a general limitation of
any pan-cancer study, we did however perform additional
analyses adjusting for COCA subtypes which captures more
molecular heterogeneity than adjusting for cancer types alone
and found analogous results; and fourth no external valida-
tion was performed for the CCS signature, although we are
not aware of any other pan-cancer dataset where it could be
validated and more importantly, we are not currently pro-
posing it for use in a clinical setting—rather as a general tool
to examine the cell-cycle activity of a given tumour.
In summary, this study describes the DNA mutations and
chromosomal alterations found in tumours with low, inter-
mediate and high levels of cell-cycle activity and also
demonstrates the ability of a simple cell cycle gene
expression signature to provide independent prognostic
information at a pan-cancer level.
Materials and methods
Study population and specimens
The Pan-Cancer Atlas (PanCanAtlas) project compared and
contrasted genomic and cellular differences between tumour
types profiled as part of TCGA. The project consists of 11,069
patients with primary tumours from 32 different cancer types,
including Adrenocortical carcinoma (ACC), Bladder Urothelial
Carcinoma (BLCA), Breast Invasive Carcinoma (BRCA),
Brain lower grade Glioma (LGG), Cervical squamous cell
carcinoma and endocervical adenocarcinoma (CESC), Cho-
langiocarcinoma (CHOL), Colon adenocarcinoma (COAD),
Esophageal carcinoma (ESCA), Glioblatoma multiforme
(GBM), Head and Neck squamous cell carcinoma (HNSC),
Kidney Chromophobe (KICH), Kidney renal clear cell carci-
noma (KIRC), Kidney renal papillary cell carcinoma (KIRP),
Liver hepatocellular carcinoma (LICH), Lung adenocarcinoma
(LUAD), Lung squamous cell carcinoma (LUSC), Lymphoid
Neoplasm Diffuse Large B-cell Lymphoma (DLBC), Meso-
thelioma (MESO), Ovarian serous cystadenocarcinoma (OV),
Pancreatic adenocarcinoma (PAAD), Pheochromocytoma and
Paraganglioma (PCPG), Prostate adenocarcinoma (PRAD),
Rectum adenocarcinoma (READ), Sarcoma (SARC), Skin
Cutaneous Melanoma (SKCM), Stomach adenocarcinoma
(STAD), Testicular Germ Cell tumours (TGCT), Thymoma
(THYM), Thyroid carcinoma (THCA), Uterine Carcino-
sarcoma (UCS), Uterine Corpus Endometrial Carcinoma
(UCEC) and Uveal Melanoma (UVM).
From the original 11,069 patients, 9515 were included
in our study and reasons for exclusion were missing or no
matching gene expression data (n= 795), copy number
data (n= 498) or clinico-pathological information (n=
261). A CONSORT diagram showing the exclusion cri-
teria for this study is shown in Supplementary Fig. 1. This
cohort was chosen owing to its large sample size ensuring
sufficient power for the statistical testing being performed.
All clinical, gene expression, mutation and chromosome
arm-level data from the PanCanAtlas study were taken
from the publicly available database of the National
Institutes of Health (NIH) (https://gdc.cancer.gov/about-da
ta/publications/pancanatlas).
mRNA data, clustering and the Cell Cycle Score (CCS)
Fully processed, batch corrected, RNA-sequencing data
were accessed from NIH genomic data commons (GDC)
database (https://gdc.cancer.gov). All data quality control,
normalisation and gene level counts were performed by the
PanCanAtlas investigators as described in the their original
publication [25]. iCluster were also retrieved from the same
publication. COCA classifications were performed by the
pan-can investigators as described in Hoadley et al. [7],
resulting in 32 different tumour clusters. Clusters with <20
tumours were excluded from further analysis.
The CCS signature is comprised of 463 genes that were
originally identified through the aggregation of three different
pathway-related databases—KEGG, HGNC and Cyclebase 3.0
[16–18]. As these databases aim to describe general biology
rather than being cancer focused, the CCS genes can be seen as
representative of general cell-cycle activity and could be
applied to any tissue sample (normal or tumour tissue). Whilst
the signature has previously been applied in a breast cancer
setting, the gene list has not been reduced or altered on the
basis of those studies. For the sake of clarity and reproduci-
bility all 463 signature genes are shown in Supplementary
Table 1 along with annotations of which genes were present in
previous breast cancer studies as well as the current pan-cancer
dataset. Four hundred and forty-one of the 463 original CCS
signature genes were present in, and extracted from, the pan-
cancer dataset. Expression values were summed on an indivi-
dual tumour basis to derive a single score of cell-cycle activity
for each sample. This continuous variable was further divided
into tertiles in order to classify tumours as having Low,
Intermediate or High levels of cell-cycle activity on a broad,
pan-cancer level. Cancer types where the pan-cancer CCS
demonstrated independent prognostic information in multi-
variable Cox proportional hazard models were also assessed
using within (intra-) cancer CCS tertiles: KIRC, LGG, SARC
and UVM.
Mutational analysis
Fully processed mutational data derived from exome
sequencing was taken from GDC database in a mutation
annotation format file (MAF) (https://gdc.cancer.gov). All
data quality control, processing and mutation calling was
performed by the PanCanAtlas investigators as described in
the their original publication [8]. We limited our analysis to
299 cancer driver genes manually annotated by experts in the
pan-cancer field [8]. The MAFtools package in the R-
statistical environment was used for mutation count calcula-
tions within CCS subgroups. A gene was counted as mutated
(1) or not (0) for each tumour regardless of the number of
mutations within that gene.
Chromosomal arm-level alterations and aneuploidy
score
Fully processed chromosome arm-level alteration data and
tumour aneuploidy scores were accessed from GDC data-
base (https://gdc.cancer.gov) and were derived from Affy-
metrix SNP 6.0 arrays. All data quality control and
processing was performed by the PanCanAtlas investigators
as described in the original publication [26]. Chromosome
arm-level alterations are presented as estimated ploidy
values of +1, 0 and −1 for gains, non-aneuploidy and
losses, respectively [9].
Statistical analysis
To assess differences among clinico-pathological character-
istics of tumour samples and CCS subgroups χ2 tests were
employed. Clinical and survival data were retrieved from the
GDC database (https://gdc.cancer.gov/about-data/publications/
pancanatlas). Univariate Kaplan–Meier analysis was per-
formed for the CCS in all pan-cancer tumours together and in
individual cancer types with PFI censored at 15 years as the
clinical endpoint, as previously recommended [19]. PFI is
defined as the period during or after the course of a treatment
given to patients in which the disease does not show any
progression until a loco-regional recurrence and/or second
malignancy occurs, or the patients die from any cause. Mul-
tivariable Cox proportional hazard models were used to
determine the independent prognostic capacity of the CCS
subgroups in all pan-cancer tumours together and in individual
cancer types adjusting for cancer type, age (grouped in ter-
tiles), gender, radiation therapy and pathological stage.
Tumour grading information was missing for over 50% of
pan-cancer samples and as such was not included in multi-
variable analyses. To compare the prognostic capacity of pan-
cancer vs. intra-cancer CCS cutoffs we used the LR, which can
be interpreted as a goodness-of-fit test. LR and concordance
index (C-index) measures were extracted from the output of
the coxph function of the survival package in R. Genomic
alterations including the frequency of gene mutations and
chromosomal arm gains and losses as well as aneuploidy score
were compared between three CCS subgroups by using
ANOVA with the post-hoc Tukey HSD test, all tests were
two-sided and p < 0.05 was considered as statistically sig-
nificant, *p < 0.05, **p < 0.01, ***p < 0.001. All p values in
the Kaplan–Meier curves were corrected for multiple com-
parisons using the Benjamini & Hochberg method. The data
fulfilled the preconditions/assumption of the above tests.
Continuous CCS was normally distributed and variation was
<1% between groups. All statistical analyses were performed
using R-statistical software version 3.5.3 [27].
Data availability




R-code to reproduce the main and Supplementary results of
this study are publicly available at https://github.com/aria
nlundberg/PANCAN.analysis.
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